China's Asymchem Q3 revenue, net profit rise on macromolecules strength
Overview
China CDMO's Q3 revenue rose 24% yr/yr to RMB 1.79 bln
Net profit attributable to shareholders increased 81.5% yr/yr
Growth driven by chemical macromolecules, biological macromolecules, and drug product segments
Outlook
Company expects full-year 2026 operating revenue to increase by 19% to 22%
Q4 delivery scale is expected to increase significantly versus Q3, supported by its order backlog
Result Drivers
MACROMOLECULAR SEGMENTS - Co said Q3 growth was mainly driven by strong performance in chemical macromolecules, biological macromolecules, and drug product segments
EMERGING BUSINESS GROWTH - Revenue from emerging businesses rose sharply, with gross profit margin of 30.95% in Q3
OPERATING EFFICIENCY - Co said shift to 'cost control and efficiency improvement' approach enhanced profitability and competitiveness
Company press release: Full Story
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | RMB 1.79 bln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Asymchem Laboratories (Tianjin) Co Ltd is CNY191.70, about 37.3% above its October 22 closing price of CNY139.66
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 37 three months ago
Reuters Recommended Reads
Oct 20 - Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised
Oct 21 - Integra Lifesciences Q3 revenue slightly misses estimates on flood damage
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)